Last updated: Jul 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07501117 | 1 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | CTLA-4 + PD-1 -- immune checkpoint inhibitors (monoclonal antibodies) |
| NCT06246149 | 3 | Adjuvant Tebentafusp in High Risk Ocular Melanoma | gp100 peptide-HLA complex -- bispecific T cell engager (ImmTAC) |
| NCT06961357 | 1, 2 | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | CD40L + tumor antigens -- CD40L-augmented tumor infiltrating lymphocytes (cell therapy) |
| NCT06932757 | 2 | Adjuvant Quisinostat in High-Risk Uveal Melanoma | Histone deacetylases (HDAC) -- HDAC inhibitor (small molecule) |
| NCT07636785 | 1, 2 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| Vastra Gotaland Region | 3 |
| H. Lee Moffitt Cancer Center and Research Institute | 3 |
| University of Miami | 2 |
| Thomas Jefferson University | 2 |
| St Vincent's Hospital, Sydney | 2 |
Countries/regions with the most active trial sites for uveal melanoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jun 29, 2026 | NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | CTLA-4 + PD-1 -- immune checkpoint inhibitors (monoclonal antibodies) |
| Mar 2, 2026 | NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | CSPG4 + GD2 -- dual-target chimeric antigen receptor natural killer cells (CAR-NK) |
| Mar 2026 | NCT07183852 | Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma | Tumor-infiltrating lymphocytes + melphalan + IL-2 -- adoptive cell therapy + chemotherapy + cytokine |
| Feb 1, 2026 | NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis | PI3Kdelta -- small molecule inhibitor (Roginolisib) |
| Dec 3, 2025 | NCT06961357 | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | CD40L + tumor antigens -- CD40L-augmented tumor infiltrating lymphocytes (cell therapy) |
| Nov 19, 2025 | NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma | Tumor antigen targeted alpha-emitter radiopharmaceutical -- targeted radiotherapy |
| Oct 15, 2025 | NCT06626516 | Tebentafusp-tebn With LDT in Metastatic UM | gp100 peptide-HLA-A*0201 + T cell receptor -- bispecific T cell engager (ImmTAC) |
You've seen the uveal melanoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.